Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-14)

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1351-1355

  Garden, Adam S ^a   Harris, Jonathan ^b   Trotti, Andy ^c   Jones, Christopher U ^d   Carrascosa, Luis ^e   Cheng, Jonathan D ^e   Spencer, Sharon S ^f   Forastiere, Arlene ^g   Weber, Randal S ^a   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Radiological Associates of Sacramento Medical Group Inc   (United States)

^e University of Louisville School of Medicine   (United States)

^f The University of Alabama at Birmingham   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Accelerated radiotherapy; Chemoradiation; Late toxicity; Radiation

Indexed keywords

CISPLATIN (CDDP); CONCURRENT CISPLATIN (CDDP); HEAD AND NECK; PHASE II; STAGE III;

PLATINUM COMPOUNDS;

CISPLATIN; GRANISETRON; ONDANSETRON;

ADVANCED CANCER; ARTICLE; CANCER CONTROL; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DISEASE COURSE; FATIGUE; FOLLOW UP; GASTROSTOMY; HEAD AND NECK CARCINOMA; HEARING IMPAIRMENT; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; RESPIRATORY DISTRESS; SEPSIS; SKIN TOXICITY; SURVIVAL RATE; TREATMENT FAILURE; WEIGHT REDUCTION;

CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; GASTROSTOMY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 47149113166     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.006     Document Type: Article

References (14)

1. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 (2000) 949-955
2. Al-Sarraf M., LeBlanc M., Giri P., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
3. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
4. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
5. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
6. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
7. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Physics 48 (2000) 7-16
8. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
9. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group Phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
10. Cox J., Stetz J., and Pajak T. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Physics 32 (1995) 567-576
11. Cox D.R. Regression models and life tables. J Roy Stat Soc B 34 (1972) 187-229
12. Kalbfleish J., and Prentice R. The statistical analysis of failure time data (1980), Wiley, New York
13. Bourhis J., Guigay J., Temam S., et al. Chemo-radiotherapy in head and neck cancer. Ann Oncol 17 Suppl. 10 (2006) x39-x41
14. Eisbruch A., Ship J., Dawson L., et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 27 (2003) 832-837